All Stories

  1. Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta‐Analysis, and Meta‐Regression

    Article • European Journal of Neurology, August 2026, Wiley

    Dr. Francesco Saccà

  2. Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

    Article • Annals of Clinical and Translational Neurology, April 2026, Wiley

    Dr. Francesco Saccà

  3. Localized Changes in Dentate Nucleus Shape and Magnetic Susceptibility in Friedreich Ataxia

    Article • Movement Disorders, April 2024, Wiley

    Dr. Francesco Saccà

  4. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis

    Article • European Journal of Neurology, March 2024, Wiley

    Dr. Francesco Saccà

  5. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy

    Article • European Journal of Neurology, December 2023, Wiley

    Dr. Francesco Saccà

  6. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis

    Article • European Journal of Neurology, May 2023, Wiley

    Dr. Francesco Saccà

  7. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence

    Article • Journal of Clinical Medicine, February 2023, MDPI AG

    Dr. Francesco Saccà

  8. The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients

    Article • The Cerebellum, September 2022, Springer Science + Business Media

    Dr. Francesco Saccà

  9. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

    Article • Multiple Sclerosis Journal, March 2022, SAGE Publications

    Dr. Francesco Saccà

  10. Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis

    Article • International Neurourology Journal, December 2021, Korean Continence Society (KAMJE)

    Dr. Francesco Saccà

  11. A real‐world study of alemtuzumab in a cohort of Italian patients

    Article • European Journal of Neurology, October 2021, Wiley

    Dr. Francesco Saccà

  12. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy

    Article • Multiple Sclerosis Journal, April 2021, SAGE Publications

    Dr. Francesco Saccà

  13. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

    Article • Multiple Sclerosis and Related Disorders, July 2020, Elsevier

    Dr. Francesco Saccà

  14. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study

    Article • Multiple Sclerosis and Related Disorders, February 2020, Elsevier

    Dr. Francesco Saccà

  15. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series

    Article • Multiple Sclerosis and Related Disorders, January 2020, Elsevier

    Dr. Francesco Saccà

  16. The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series

    Article • Neurological Sciences, November 2019, Springer Science + Business Media

    Dr. Francesco Saccà

  17. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families

    Article • European Journal of Neurology, November 2019, Wiley

    Dr. Francesco Saccà

  18. Overt hypogonadism may be not a sentinel sign of RNF216 : two novel mutations associated with ataxia, chorea and fertility

    Article • Movement Disorders Clinical Practice, September 2019, Wiley

    Dr. Francesco Saccà

  19. Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis

    Article • Multiple Sclerosis and Related Disorders, January 2019, Elsevier

    Dr. Francesco Saccà

  20. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis

    Article • Multiple Sclerosis and Related Disorders, October 2018, Elsevier

    Dr. Francesco Saccà

  21. Cognitive and functional connectivity alterations in Friedreich's ataxia

    Article • Annals of Clinical and Translational Neurology, April 2018, Wiley

    Dr. Francesco Saccà

  22. Dissociative identity disorder: Restoration of executive functions after switch from alter to host personality

    Article • Psychiatry and Clinical Neurosciences, February 2018, Wiley

    Dr. Francesco Saccà

  23. Peripheral markers of autophagy in polyglutamine diseases

    Article • Neurological Sciences, October 2017, Springer Science + Business Media

    Dr. Francesco Saccà

  24. The Multiple Faces of Spinocerebellar Ataxia type 2

    Article • Annals of Clinical and Translational Neurology, August 2017, Wiley

    Dr. Francesco Saccà

  25. Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests

    Article • Journal of Neuropsychology, May 2017, Wiley

    Dr. Francesco Saccà

  26. The iEDSS: BICAMS for the Cerebral Functional Score

    Article • Multiple Sclerosis Journal, November 2016, SAGE Publications

    Dr. Francesco Saccà

  27. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection

    Article • Neurological Sciences, October 2016, Springer Science + Business Media

    Dr. Francesco Saccà

  28. The use of medical-grade cannabis in patients non-responders to Nabiximols

    Article • Journal of the Neurological Sciences, September 2016, Elsevier

    Dr. Francesco Saccà

  29. Mobitz type I and II atrioventricular blocks during fingolimod therapy

    Article • Neurological Sciences, May 2016, Springer Science + Business Media

    Dr. Francesco Saccà

  30. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia

    Article • Movement Disorders, February 2016, Wiley

    Dr. Francesco Saccà

  31. Modifications of resting state networks in spinocerebellar ataxia type 2

    Article • Movement Disorders, June 2015, Wiley

    Dr. Francesco Saccà

  32. Multiple hormone deficiencies in chronic heart failure

    Article • International Journal of Cardiology, April 2015, Elsevier

    Dr. Francesco Saccà

  33. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis

    Article • European Journal of Radiology, January 2015, Elsevier

    Dr. Francesco Saccà

  34. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2014, Springer Science + Business Media

    Dr. Francesco Saccà

  35. Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD)

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2014, Springer Science + Business Media

    Dr. Francesco Saccà

  36. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

    Article • BMC Neurology, April 2014, Springer Science + Business Media

    Prof Alessandra Lugaresi, Dr. Francesco Saccà

  37. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

    Article • Movement Disorders, February 2014, Wiley

    Dr. Francesco Saccà

  38. Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania

    Article • Journal of Parkinson’s Disease, January 2014, IOS Press

    Dr. Francesco Saccà

  39. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis

    Article • Human Molecular Genetics, November 2013, Oxford University Press (OUP)

    Dr. Francesco Saccà

  40. A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease

    Article • JAMA Neurology, January 2013, American Medical Association (AMA)

    Dr. Francesco Saccà

  41. Migraine attack restores the response of vascular smooth muscle cells to nitric oxide but not to norepinephrine

    Article • World Journal of Cardiology, January 2013, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr. Francesco Saccà

  42. Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2012, Springer Science + Business Media

    Dr. Francesco Saccà

  43. A randomized clinical trial of lithium in multiple system atrophy

    Article • Deutsche Zeitschrift für Nervenheilkunde, August 2012, Springer Science + Business Media

    Dr. Francesco Saccà

  44. A gene expression phenotype in lymphocytes from friedreich ataxia patients

    Article • Annals of Neurology, November 2011, Wiley

    Dr. Francesco Saccà

  45. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 2011, Springer Science + Business Media

    Dr. Francesco Saccà

  46. A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design

    Article • PLOS One, March 2011, PLOS

    Dr. Francesco Saccà

  47. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit

    Article • Movement Disorders, November 2010, Wiley

    Dr. Francesco Saccà

  48. Benign hereditary chorea: Clinical and neuroimaging features in an Italian family

    Article • Movement Disorders, June 2010, Wiley

    Dr. Francesco Saccà

  49. Vascular smooth muscle cell dysfunction in patients with migraine

    Article • Neurology, June 2009, Wolters Kluwer Health

    Dr. Francesco Saccà

  50. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia

    Article • Neurology, August 2008, Wolters Kluwer Health

    Dr. Francesco Saccà

  51. Recombinant Human Erythropoietin Increases Frataxin Protein Expression Without Increasing mRNA Expression

    Article • The Cerebellum, June 2008, Springer Science + Business Media

    Dr. Francesco Saccà

  52. Ataxia with oculomotor apraxia type 2: A clinical, pathologic, and genetic study

    Article • Neurology, April 2006, Wolters Kluwer Health

    Dr. Francesco Saccà

  53. Novel mutation ofSACSgene in a Spanish family with autosomal recessive spastic ataxia

    Article • Movement Disorders, October 2005, Wiley

    Dr. Francesco Saccà

  54. Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation

    Article • Deutsche Zeitschrift für Nervenheilkunde, March 2005, Springer Science + Business Media

    Dr. Francesco Saccà

  55. Very late onset in ataxia oculomotor apraxia type I

    Article • Annals of Neurology, January 2005, Wiley

    Dr. Francesco Saccà